Immorta Bio Pioneers AI-Designed Senolytic Immunotherapy Targeting Diseases of Aging
Breakthrough Nine-Amino-Acid Peptide Designed to Restore the Immune System's Ability to Eliminate Senescent Cells, With Clinical Entry Planned for 2026 MIAMI, Oct. 12, 2026 /PRNewswire/ -- Immorta Bio, Inc., a biotechnology company pioneering therapies targeting fundamental mechanisms of...
Covered in this story
Call it yourself
No calls on $NINE yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Nine Energy Service →Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.